Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Background: Cell therapy (CTh) is a promising novel therapy for myocardial infarction (MI) and ischemic cardiomyopathy (iCMP). Recognizing adverse events (AE) is important for safety evaluation, harm prevention and may aid in the design of future trials.

Objective: To define the prevalence of periprocedural AE in CTh trials in MI and iCMP.